Analysts have been eager to weigh in on the Healthcare sector with new ratings on Foamix Pharma (NASDAQ:FOMX) and Bausch Health Companies Inc (NYSE:BHC).
Foamix Pharma (FOMX)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Foamix Pharma, with a price target of $11. The company’s shares closed on Friday at $5.05.
Selvaraju said:
“Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) of FMX101 is $400M, which factors in an 85% probability of success that reflects the impact of the positive data from the most recently reported Phase 3 trial. We have employed a sum-of-the-parts valuation approach that ascribes a total projected firm value of $645M, which translates into a price objective of $11.00 assuming ~57.5M fully-diluted shares outstanding as of end-3Q19.”
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.9% and a 38.5% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
Foamix Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $20.50.
See today’s analyst top recommended stocks >>
Bausch Health Companies Inc (BHC)
RBC Capital analyst Douglas Miehm maintained a Hold rating on Bausch Health Companies Inc today and set a price target of $30. The company’s shares closed on Friday at $26.32, close to its 52-week high of $28.45.
According to TipRanks.com, Miehm has currently no stars on a ranking scale of 0-5 stars, with an average return of -8.2% and a 43.9% success rate. Miehm covers the Healthcare sector, focusing on stocks such as Novelion Therapeutics Inc, CRH Medical Corporation, and Shire.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bausch Health Companies Inc with a $25.60 average price target, representing a -2.7% downside. In a report issued on October 1, H.C. Wainwright also reiterated a Hold rating on the stock with a $25 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
